European Medicines Agency’s CHMP Rejects Celgene’s Revlimid In Myelodysplastic Syndromes
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency reiterates negative opinion on Wyeth's Mylotarg for acute myeloid leukemia.
You may also be interested in...
Celgene Withdraws EU Filing For Revlimid After Second CHMP Refusal
Company counters setback by unveiling promising lenalidomide data from NHL, newly diagnosed multiple myeloma trials during ASCO.
Celgene Withdraws EU Filing For Revlimid After Second CHMP Refusal
Company counters setback by unveiling promising lenalidomide data from NHL, newly diagnosed multiple myeloma trials during ASCO.
CHMP’s Revlimid Rebuff Will Have Limited Impact In EU Market
Analyst calls vote “more of a psychological setback” than anything, as drug already is approved on named-patient basis.